Are you ready for the next decade's pharmaceutical heavyweight products?

Source: the competition between praluent, jointly developed by BIOON 2015-7-61, PCSK9 inhibitor - dyslipidemia Sanofi and regeneron, and repatha, Amgen, has entered the final stage of hyperthermia It is estimated that they will obtain the approval of FDA on July 24 and August 27 The current FDA opinion is that the two new drugs can be used in patients with dyslipidemia, which is not easy to cure, but not in patients who are intolerant to statins If we want to expand the scope of adaptation, we need more convincing clinical data Pfizer has also entered the PCSK9 inhibitor market, the rising star can not be ignored The U.S medical system also hopes PCSK9 inhibitors can reduce medical costs 2 Pfizer, the CDK4 / 6 kinase inhibitor of breast cancer, announced that ibrance means its return to the focus of research and development Ibrance can treat hormone receptor positive (HR +), human epidermal growth factor receptor 2 negative (HER2 -) metastatic breast cancer Next, ibrance had to face the strong impact of Novartis drug lee001 and Lilly abemaciclib 3 PD-1 / PD-L1 inhibitors - non-small cell lung cancer PD-1 / PD-L1 inhibitors are suitable for many types of tumors Non-small cell lung cancer is the most representative indication and the largest battlefield Bristol Myers Squibb opdivo, Merck keytruda, Roche atezolizumab and AstraZeneca's medi-4736 are all targeting this market Bristol Myers Squibb opdivo is the most popular because of its strong position in the second-line treatment of non-small cell lung cancer, although the company's biomarker strategy has raised some questions In the first-line treatment, different companies have adopted different strategies, such as Roche's combination of atezolizumab and chemotherapy If clinical trials prove that its efficacy is extraordinary, the treatment may become the focus of the industry 4 Is IL-17 inhibitor psoriasis a top three competition or a duel? Brodalumab, the IL-17 inhibitor of AstraZeneca, was defeated due to safety issues, and Novartis' cosantyx was brilliant Cosantyx 1 was approved by the United States and Europe in January, and it is expected to win a lot of money for Novartis Clinicians and industry leaders also seem to be very optimistic about cosentix In addition, Lilly's clinical data of IL-17 inhibitors at the end of the period is ideal, and it will enter the public view in the next few months 5 CGRP inhibitors - migraine CGRP, calcitonin gene-related peptide Alderbio pharmaceuticals, Amgen, Lilly and Teva are all in the same pace in the research of CGRP inhibitors, which one will take the lead? This will be an event to look forward to in the next five years According to the current mid-term research data, CGRP inhibitors have good clinical effect and tolerance It is estimated that the peak annual revenue generated is between 8 billion US dollars and 10 billion US dollars 6 Nonalcoholic steatohepatitis was originally considered as the last disease in the field of medicine, but now she has been targeted by many pharmaceutical companies Intercept pharmaceuticals released the interim clinical data of obacholic acid (OCA) for nonalcoholic steatohepatitis last year Intercept is very confident about OCA's No.1 position in this field There are already many pharmaceutical and biological companies in the process of research and development 7 Ofev of bringer Ingelheim and esbrit of Roche successively entered the market of idiopathic pulmonary fibrosis, the latter entered through the acquisition of intermune At present, this field is so popular that many companies have invested in relevant R & D projects 8 Three in one combination therapy - COPD / asthma at present, breoellipta of GlaxoSmithKline has been approved by FDA, and anoro ellipta is also in the ascendant Let alone the commercial challenges of these two therapies, GlaxoSmithKline and AstraZeneca have started to study the three in one combination therapy - to focus Laba, Lama and ICs in one inhaler Novartis is also working on a three in one combination, but not COPD, but asthma However, Boehringer Ingelheim was not keen on the treatment because of the increasing environmental constraints on medical payment in the United States 9 The new generation of basic insulin diabetes Sanofi toujeo has been approved by FDA, and tresiba of Novo Nordisk may be approved by the end of 2015 The two new drugs represent a new generation of basic insulin, and are expected to outperform Sanofi Lantus, which produces $7 billion a year And clinicians, who are also the payers of drugs, have to consider another factor - price pressure, so it's unclear whether the new generation of insulin will sell well in the United States Lilly released Lantus's biosimilars, which were approved in Europe this year or in the United States next year The competition is intense 10 Biosimilars, the most interesting challenge competition of monoclonal antibody in the next decade is probably biosimilars Tumor necrosis factor inhibitors for rheumatic diseases and skin diseases and enalapril, Avastin, Herceptin and rituximab for cancer may all have similar products Whether it is the original brand or the imitators who come from behind are likely to achieve great business success, and it is also possible for the pattern of pharmaceutical companies to change greatly.